Research ArticleHuman Study
Dosimetry of Rhenium-186-Labeled Monoclonal Antibodies: Methods, Prediction from Technetium-99m-Labeled Antibodies and Results of Phase I Trials
Hazel B. Breitz, Darrell R. Fisher, Paul L. Weiden, James S. Durham, Barbara A. Ratliff, Michael J. Bjorn, Paul L. Beaumier and Paul G. Abrams
Journal of Nuclear Medicine June 1993, 34 (6) 908-917;
Hazel B. Breitz
Darrell R. Fisher
Paul L. Weiden
James S. Durham
Barbara A. Ratliff
Michael J. Bjorn
Paul L. Beaumier


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Dosimetry of Rhenium-186-Labeled Monoclonal Antibodies: Methods, Prediction from Technetium-99m-Labeled Antibodies and Results of Phase I Trials
Hazel B. Breitz, Darrell R. Fisher, Paul L. Weiden, James S. Durham, Barbara A. Ratliff, Michael J. Bjorn, Paul L. Beaumier, Paul G. Abrams
Journal of Nuclear Medicine Jun 1993, 34 (6) 908-917;
Dosimetry of Rhenium-186-Labeled Monoclonal Antibodies: Methods, Prediction from Technetium-99m-Labeled Antibodies and Results of Phase I Trials
Hazel B. Breitz, Darrell R. Fisher, Paul L. Weiden, James S. Durham, Barbara A. Ratliff, Michael J. Bjorn, Paul L. Beaumier, Paul G. Abrams
Journal of Nuclear Medicine Jun 1993, 34 (6) 908-917;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Enhanced Therapeutic Index of Radioimmunotherapy (RIT) in Prostate Cancer Patients: Comparison of Radiation Dosimetry for 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid (DOTA)-Peptide versus 2IT-DOTA Monoclonal Antibody Linkage for RIT
- Two-Step Targeting of Xenografted Colon Carcinoma Using a Bispecific Antibody and 188Re-Labeled Bivalent Hapten: Biodistribution and Dosimetry Studies
- Phase I Therapy Study of 186Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck
- How Far Have We Come with Solid (Nonhematologic) Tumor Radioimmunotherapy?